Literature DB >> 23999211

Haematological cancer: rituximab maintenance improves the outcome of elderly patients with FL.

Bryony Jones.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23999211     DOI: 10.1038/nrclinonc.2013.164

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.

Authors:  Umberto Vitolo; Marco Ladetto; Carola Boccomini; Luca Baldini; Federico De Angelis; Alessandra Tucci; Barbara Botto; Annalisa Chiappella; Annalisa Chiarenza; Antonello Pinto; Amalia De Renzo; Francesco Zaja; Claudia Castellino; Alessia Bari; Isabel Alvarez De Celis; Andrea Evangelista; Guido Parvis; Enrica Gamba; Chiara Lobetti-Bodoni; Giovannino Ciccone; Giuseppe Rossi
Journal:  J Clin Oncol       Date:  2013-08-19       Impact factor: 44.544

  1 in total
  2 in total

Review 1.  Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Authors:  Erika Vacchelli; Jonathan Pol; Norma Bloy; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jérôme Galon; Aurélien Marabelle; Holbrook Kohrt; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 2.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.